BR0212969A - Formulação farmacêutica, uso da mesma, método para a profilaxia e/ou para o tratamento de um distúrbio cardiovascular, e, processo para a preparação de uma formulação farmacêutica - Google Patents

Formulação farmacêutica, uso da mesma, método para a profilaxia e/ou para o tratamento de um distúrbio cardiovascular, e, processo para a preparação de uma formulação farmacêutica

Info

Publication number
BR0212969A
BR0212969A BR0212969-8A BR0212969A BR0212969A BR 0212969 A BR0212969 A BR 0212969A BR 0212969 A BR0212969 A BR 0212969A BR 0212969 A BR0212969 A BR 0212969A
Authority
BR
Brazil
Prior art keywords
pharmaceutical formulation
treatment
preparation
cardiovascular disorder
formulation
Prior art date
Application number
BR0212969-8A
Other languages
English (en)
Inventor
Abrahmsen Alami
Anette Larson
Jan-Erik L Froth
Adam Rosinski
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR0212969A publication Critical patent/BR0212969A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"FORMULAçãO FARMACêUTICA, USO DA MESMA, MéTODO PARA A PROFILAXIA E/OU PARA O TRATAMENTO DE UM DISTúRBIO CARDIOVASCULAR, E, PROCESSO PARA A PREPARAçãO DE UMA FORMULAçãO FARMACêUTICA". A presente invenção provê, por exemplo, uma formulação farmacêutica para administração oral que compreende H 376/95, dodecil sulfato de sódio (SDS) e um polímero selecionado do grupo que compreende hidroxipropilmetil celulose (HPMC), hidroxietil celulose (HEC) e óxido de polioxietileno (PEO), um processo para a preparação de tal formulação e o uso medicinal da formulação no tratamento de tromboembolia.
BR0212969-8A 2001-10-09 2002-10-08 Formulação farmacêutica, uso da mesma, método para a profilaxia e/ou para o tratamento de um distúrbio cardiovascular, e, processo para a preparação de uma formulação farmacêutica BR0212969A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0103369A SE0103369D0 (sv) 2001-10-09 2001-10-09 Pharmaceutical formulation
PCT/SE2002/001827 WO2003030942A1 (en) 2001-10-09 2002-10-08 Pharmaceutical formulation

Publications (1)

Publication Number Publication Date
BR0212969A true BR0212969A (pt) 2004-10-13

Family

ID=20285599

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0212969-8A BR0212969A (pt) 2001-10-09 2002-10-08 Formulação farmacêutica, uso da mesma, método para a profilaxia e/ou para o tratamento de um distúrbio cardiovascular, e, processo para a preparação de uma formulação farmacêutica

Country Status (14)

Country Link
US (1) US20040235727A1 (pt)
EP (1) EP1436009A1 (pt)
JP (1) JP2005508946A (pt)
KR (1) KR20040044197A (pt)
CN (1) CN1564695A (pt)
BR (1) BR0212969A (pt)
CA (1) CA2458473A1 (pt)
IL (1) IL161001A0 (pt)
MX (1) MXPA04003112A (pt)
NO (1) NO20041236L (pt)
NZ (1) NZ531813A (pt)
SE (1) SE0103369D0 (pt)
WO (1) WO2003030942A1 (pt)
ZA (1) ZA200402731B (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100120906A1 (en) * 2008-07-18 2010-05-13 Valeant Pharmaceuticals International Modified release formulation and methods of use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4540566A (en) * 1984-04-02 1985-09-10 Forest Laboratories, Inc. Prolonged release drug dosage forms based on modified low viscosity grade hydroxypropylmethylcellulose
AR005245A1 (es) * 1995-12-21 1999-04-28 Astrazeneca Ab Prodrogas de inhibidores de trombina, una formulación farmaceutica que las comprende, el uso de dichas prodrogas para la manufactura de un medicamento y un procedimiento para su preparacion
JPH10152431A (ja) * 1996-08-02 1998-06-09 Hisamitsu Pharmaceut Co Inc 経口製剤用カプセルと経口カプセル製剤
DE19637082A1 (de) * 1996-09-12 1998-03-19 Boehringer Mannheim Gmbh Schnellzerfallende Pellets
SE9603480L (sv) * 1996-09-23 1998-03-24 Johan Carlfors Beredningsform för svårlösliga läkemedel
US6099862A (en) * 1998-08-31 2000-08-08 Andrx Corporation Oral dosage form for the controlled release of a biguanide and sulfonylurea
SE9802973D0 (sv) * 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
SI20150A (sl) * 1999-02-19 2000-08-31 Lek, Tovarna Farmacevtskih In Direktno stisljivi matriks za nadzorovano sproščanje celodnevne doze klaritromicina
KR100416242B1 (ko) * 1999-12-22 2004-01-31 주식회사 삼양사 약물전달체용 생분해성 블록 공중합체의 액체 조성물 및이의 제조방법

Also Published As

Publication number Publication date
WO2003030942A1 (en) 2003-04-17
ZA200402731B (en) 2005-01-13
CA2458473A1 (en) 2003-04-17
IL161001A0 (en) 2004-08-31
NO20041236L (no) 2004-03-24
KR20040044197A (ko) 2004-05-27
JP2005508946A (ja) 2005-04-07
SE0103369D0 (sv) 2001-10-09
MXPA04003112A (es) 2004-07-27
NZ531813A (en) 2006-03-31
EP1436009A1 (en) 2004-07-14
CN1564695A (zh) 2005-01-12
US20040235727A1 (en) 2004-11-25

Similar Documents

Publication Publication Date Title
ES2110377T1 (es) Formulacion galenica de fenofibrato y aplicacion de la misma.
AR024227A1 (es) Pirimidinas inhibidoras de replicacion de hiv, un proceso para su preparacion, el uso de las mismas para la manufactura de un medicamento, composiciones farmaceuticas, y un proceso para prepararlas
EP1024145A3 (en) Novel azalides and methods of making same
BR9915087A (pt) Formulação farmacêutica oral revestida entérica, uso de uma qualidade de hidroxipropil celulose (hpc), processo para a munufatura de uma formulação farmacêutica oral revestida entérica, uso de uma formulação farmacêutica, e, método para o tratamento de doenças gastrointestinais em mamìferos, incluindo o homem
BRPI0408655A (pt) formulações compreendendo um agente ativo e cacau em pó e a sua utilização
BR0007151A (pt) Formulações galênicas de rápida desagregação na boca, e, processo de preparação das mesmas
ATE316083T1 (de) Adamantanderivate
AR018197A1 (es) Compuestos de piperidina, un procedimiento para su preparacion, una composicion y uso del mismo para la preparacion de un medicamento
NO180517C (no) Fremgangsmåte for fremstilling av en fast, farmasöytisk enhetsformulering
TR200101088T2 (tr) Sürekli salınımlı farmasötik kompozisyon ve farmasötik olarak aktif ajanın salınma metodu
US6620410B1 (en) Hair care compositions and protection from ultraviolet radiation
ATE386725T1 (de) Heterocyclylverbindungen
BRPI0008228B8 (pt) composição farmacêutica contendo n-benzoil estaurosporina e agentes solubilizantes
PT861084E (pt) Processo e composicao melhorados para cisplatina (cddp) terapeutica
ATE85757T1 (de) Piroxicam in waessrigen loesungen enthaltende arzneizubereitungen und verfahren zu deren herstellung.
BR0210489A (pt) Formulação farmacêutica oral, processo para preparar a mesma, uso da mesa, e método para preparar um distúrbio cardiovascular em um paciente
ATE505183T1 (de) Den geschmack verdeckende auslaufsichere formulierung
HUP0105481A2 (hu) Klaritromicint vagy származékait tartalmazó gyógyászati készítmények és eljárás előállításukra, valamint alkalmazásuk
JP2005343894A (ja) 抗菌点眼剤
BR0117147A (pt) preparado de dosagem oral de desintegração instantánea
JP4585264B2 (ja) 毛髪化粧料組成物
UA41978C2 (uk) N-метил-n-[(1s)-1-феніл-2-((3s)-3-гідроксипіролідин-1-іл)етил]-2,2- дифенілацетамід гідрохлорид, спосіб його отримання та фармацевтична композиція
DE60202590D1 (de) 2h-1-benzopyran-derivate, prozesse zu ihrer herstellung und pharmazeutische zusammensetzungen
BR0212969A (pt) Formulação farmacêutica, uso da mesma, método para a profilaxia e/ou para o tratamento de um distúrbio cardiovascular, e, processo para a preparação de uma formulação farmacêutica
BR0111055A (pt) Formulação farmacêutica, e, processo para a preparação e uso da mesma

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2060 DE 29/06/2010.